Research projects

Professor Udai Banerji, Clinical Pharmacodynamics Biomarker Group

The Clinical Pharmacodynamics Biomarker Group already has validated and has functioning assays of key nodes in the PI3K signalling pathway for drugs which target this pathway. It is now developing, validating and running assays focusing on DNA damage repair, such as p-CHK1 and gamma H2AX and also related to the cell cycle such as p-RB and p-HH3. In addition to these, the group has a wider focus of assays to study drugs targeting the alpha folate receptor such as shed circulating alpha folate receptor and cytokine assays for immunotherapy studies.